Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BTG plc
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.
US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.
Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
- Specialty Pharmaceuticals
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Biocompatibles International plc
- Ekos Corporation
- Galil Medical, Inc.
- Novate Medical Ltd.
- PneumRx Inc.
- Protherics PLC
- Roxwood Medical